Thrombocytosis and Hyperfibrinogenemia Are Predictive Factors of Clinical Outcomes in High-Grade Serous Ovarian Cancer Patients

BMC Cancer - United Kingdom
doi 10.1186/s12885-016-2070-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

New in High Grade Serous Ovarian Cancer Treatment

Effective Pharmacotherapy
2019English

Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer

Frontiers in Genetics
GeneticsMolecular Medicine
2020English

Distinct Gene Expression Profiles Associated With Clinical Outcomes in Patients With Ovarian Clear Cell Carcinoma and High-Grade Serous Ovarian Carcinoma

Journal of Ovarian Research
GynecologyOncologyObstetrics
2020English

Predictors of Long-Term Survival Among High-Grade Serous Ovarian Cancer Patients

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2019English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Diffusion Kurtosis MRI as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy in High Grade Serous Ovarian Cancer

Scientific Reports
Multidisciplinary
2019English

Predictive and Prognostic Relevance of P53 in Patients With Serous Epithelial Ovarian Cancer

Benha Medical Journal
2020English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Low-Stage High-Grade Serous Ovarian Carcinomas

International Journal of Gynecological Pathology
GynecologyForensic MedicinePathologyObstetrics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy